Dual-acting and Multi-targeting Therapeutic Agents
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Bioorganic Chemistry".
Deadline for manuscript submissions: closed (15 December 2020) | Viewed by 2616
Special Issue Editor
Interests: design of targeted epigenetic modifying small molecules; design of tissue selective anti-fibrosis small molecules; design of selective TBK1/IKKe inhibitors; molecular delivery – cell-selective delivery of functional nanoparticles; nucleic acid biochemistry and biophysics – interaction of RNAs with small molecules
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The one-ligand-one-target-one-disease approach is a true and tested drug design principle that has successfully furnished therapeutic agents for several human and veterinary indications. An open secret is that drugs rarely interact with just one target—i.e., they are pleiotropic. Pleiotropy is a two-edged sword as it could be the cause of adverse side effects or vital to the therapeutic effects of the drugs. The recognition of the positive attributes of pleiotropy has given rise to interest in intentionally designed dual- and/or multi-acting drugs (polypharmacological agents). The underpinning objective of research in this field is to identify a new generation of polypharmacological agents that are more efficacious in treating complex diseases such as cancer, metabolic, immunological, and neurological disorders. Major advances have been made in the last decade with the successful introduction of several deliberately designed polypharmacological agents into clinical use. The goal of this Special Issue of Molecules is to provide a medium for researchers to share their new findings on the identification of a new generation of polypharmacological agents, and to appraise the current state of knowledge and the challenges to be addressed in the future.
Prof. Adegboyega K. Oyelere
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Dual-acting therapeutic agents
- Multi-targeting therapeutic agents
- Designed multiple ligands
- Pleiotropy
- Complex diseases
